• LAST PRICE
    3.6900
  • TODAY'S CHANGE (%)
    0.0000 (0.0000%)
  • Bid / Lots
    3.6300/ 10
  • Ask / Lots
    3.7300/ 5
  • Open / Previous Close
    0.0000 / 3.6900
  • Day Range
    ---
  • 52 Week Range
    Low 3.4700
    High 28.9500
  • Volume
    178
    below average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table
TimeVolumeONTX
Data delayed at least 15 minutes.

Sep 28, 2021

Sep 24, 2021

4:26PM ET on Friday Sep 24, 2021 by MT Newswires

1:46PM ET on Friday Sep 24, 2021 by MT Newswires

1:12PM ET on Friday Sep 24, 2021 by Thomson Reuters
0 New Today
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesONTX
Onconova Therapeutics Inc
58.2M
-2.3x
---
United StatesSYN
Synthetic Biologics Inc
59.0M
-1.0x
---
United StatesENSC
Ensysce Biosciences Inc
59.2M
14.6x
---
United StatesCWBR
CohBar Inc
59.3M
-3.1x
---
United StatesCUBT
Curative Biotechnology Inc
56.3M
-372.5x
---
United StatesGRTX
Galera Therapeutics Inc
59.3M
-0.7x
---
As of 2021-10-20

Company Information

Onconova Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing products for patients with cancer. The Company has created a targeted anti-cancer agent designed to disrupt specific cellular pathways that are important for cancer cell proliferation. Its pipeline includes two clinical-stage programs. ON 123300 product candidate is a multi-kinase inhibitor targeting cyclin dependent kinase (CDK 4/6) and other tyrosine kinasesto to drive tumor proliferation. Its another product candidate Oral Rigosertib in combination with a PD-1 inhibitor targeting patients with K-Ras mutated non-small cell lung cancer (NSCLC).

Contact Information

Headquarters
375 Pheasant RunNEWTOWN, PA, United States 18940-3423
Phone
267-759-3680
Fax
267-759-3681

Executives

Chairman of the Board
James Marino
President, Chief Executive Officer, Director
Steven Fruchtman
Principal Financial Officer, Principal Accounting Officer, Vice President - Financial Planning & Accounting
Mark Guerin
Vice President, Corporate Development and General Counsel
Abraham Oler
Chief Medical Officer
Mark Gelder

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$58.2M
Revenue (TTM)
$236.0K
Shares Outstanding
15.8M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
1.79
EPS
$-1.63
Book Value
$0.50
P/E Ratio
-2.3x
Price/Sales (TTM)
246.7
Price/Cash Flow (TTM)
---
Operating Margin
-9,013.56%
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.